PURPOSE: Laboratory studies have suggested that vitamin D inadequacy may be implicated in development of hypertension. Evidence from epidemiologic studies remains limited. We aim to examine the prospective associations of circulating vitamin D metabolites, vitamin D receptor (VDR) gene polymorphisms, and their interaction with risk of hypertension. METHODS: We conducted prospective analyses among 1,211 US men that were free of baseline hypertension and hadbaseline plasma 25hydroxy-vitamin D (25(OH)D) or 1,25dihydroxy-vitamin D (1,25(OH)2D) measured and VDR BsmI or FokI polymorphisms genotyped. RESULTS: During 15.3-year follow-up, 695 men developed incident hypertension. After multivariable adjustment, the hazard ratios (HRs) and 95 % CIs for hypertension across increasing quartiles of plasma vitamin D metabolites were 1.00 (ref), 0.94 (0.69-1.27), 0.69 (0.50-0.96), and 0.82 (0.60-1.13) for 25(OH)D (p, trend: 0.43), and 1.00, 0.92 (0.66-1.27), 1.12 (0.82-1.54), and 1.19 (0.86-1.63) for 1,25(OH)2D (p, trend: 0.16). Compared with carriers of VDR BsmI bb, carriers of bB or BB had a HR of 1.25 (1.04-1.51) for hypertension. For VDR FokI polymorphism, compared with carriers of FF and Ff combined, carriers of ff had a HR of 1.32 (1.03-1.70). The relation between plasma 25(OH)D and risk of hypertension did not differ by VDR BsmI and FokI polymorphisms. CONCLUSIONS: In a prospective cohort of men, we found suggestive evidence for an inverse association between plasma 25(OH)D and risk of hypertension. We also found associations between VDR BsmI and FokI polymorphisms with hypertension risk. More research is needed to further determine the role of vitamin D in hypertension prevention.
RCT Entities:
PURPOSE: Laboratory studies have suggested that vitamin D inadequacy may be implicated in development of hypertension. Evidence from epidemiologic studies remains limited. We aim to examine the prospective associations of circulating vitamin D metabolites, vitamin D receptor (VDR) gene polymorphisms, and their interaction with risk of hypertension. METHODS: We conducted prospective analyses among 1,211 US men that were free of baseline hypertension and had baseline plasma 25hydroxy-vitamin D (25(OH)D) or 1,25dihydroxy-vitamin D (1,25(OH)2D) measured and VDR BsmI or FokI polymorphisms genotyped. RESULTS: During 15.3-year follow-up, 695 men developed incident hypertension. After multivariable adjustment, the hazard ratios (HRs) and 95 % CIs for hypertension across increasing quartiles of plasma vitamin D metabolites were 1.00 (ref), 0.94 (0.69-1.27), 0.69 (0.50-0.96), and 0.82 (0.60-1.13) for 25(OH)D (p, trend: 0.43), and 1.00, 0.92 (0.66-1.27), 1.12 (0.82-1.54), and 1.19 (0.86-1.63) for 1,25(OH)2D (p, trend: 0.16). Compared with carriers of VDRBsmI bb, carriers of bB or BB had a HR of 1.25 (1.04-1.51) for hypertension. For VDR FokI polymorphism, compared with carriers of FF and Ff combined, carriers of ff had a HR of 1.32 (1.03-1.70). The relation between plasma 25(OH)D and risk of hypertension did not differ by VDR BsmI and FokI polymorphisms. CONCLUSIONS: In a prospective cohort of men, we found suggestive evidence for an inverse association between plasma 25(OH)D and risk of hypertension. We also found associations between VDR BsmI and FokI polymorphisms with hypertension risk. More research is needed to further determine the role of vitamin D in hypertension prevention.
Authors: Jung Eun Lee; Haojie Li; Andrew T Chan; Bruce W Hollis; I-Min Lee; Meir J Stampfer; Kana Wu; Edward Giovannucci; Jing Ma Journal: Cancer Prev Res (Phila) Date: 2011-03-23
Authors: Karen L Margolis; Lisa W Martin; Roberta M Ray; Tessa J Kerby; Matthew A Allison; J David Curb; Theodore A Kotchen; Simin Liu; Sylvia Wassertheil-Smoller; Joann E Manson Journal: Am J Epidemiol Date: 2011-11-29 Impact factor: 4.897
Authors: Daniel Zehnder; Rosemary Bland; Ravinder S Chana; David C Wheeler; Alexander J Howie; Mary C Williams; Paul M Stewart; Martin Hewison Journal: J Am Soc Nephrol Date: 2002-03 Impact factor: 10.121
Authors: F Kokot; J Pietrek; S Srokowska; W Wartenberg; J Kuska; M Jedrychowska; G Duda; K Zielińska; Z Wartenberg; M Kuźmiak Journal: Clin Nephrol Date: 1981-10 Impact factor: 0.975
Authors: B K Lee; G S Lee; W F Stewart; K D Ahn; D Simon; K T Kelsey; A C Todd; B S Schwartz Journal: Environ Health Perspect Date: 2001-04 Impact factor: 9.031
Authors: Ivone F O C Nunes; Ana A C M Cavalcante; Marcus V O B Alencar; Marcos D F Carvalho; José L R Sarmento; Nayra S C C A Teixeira; Adriana A Paiva; Lídia R Carvalho; Leopoldo F M Nascimento; Maria S P Cruz; Marcelo M Rogero; Andréia C B Lima; Cecilia M R G Carvalho Journal: Adv Nutr Date: 2020-09-01 Impact factor: 8.701
Authors: Lu Wang; Audrey Chu; Julie E Buring; Paul M Ridker; Daniel I Chasman; Howard D Sesso Journal: Am J Hypertens Date: 2014-03-31 Impact factor: 2.689
Authors: Rumana J Khan; Pia Riestra; Samson Y Gebreab; James G Wilson; Amadou Gaye; Ruihua Xu; Sharon K Davis Journal: J Nutr Date: 2016-06-29 Impact factor: 4.798
Authors: Andrea Di Nisio; Luca De Toni; Elvio D'Addato; Maria R Pizzo; Pasquale Sabatino; Carlo Foresta Journal: Endocrine Date: 2015-09-01 Impact factor: 3.633
Authors: Liang Ke; Barry I Graubard; Demetrius Albanes; David R Fraser; Stephanie J Weinstein; Jarmo Virtamo; Kaye E Brock Journal: Am J Hypertens Date: 2013-04-18 Impact factor: 2.689